The effect of long-term treatment with coenzyme Q10 on nucleic acid modifications by oxidation in children with Down syndrome

Emil List Larsen; Lucia Padella; Helle Kirstine Mørup Bergholdt; Trine Henriksen; Lucia Santoro; Orazio Gabrielli; Henrik Enghusen Poulsen; Gian Paolo Littarru; Patrick Orlando; Luca Tiano

doi:10.1016/j.neurobiolaging.2018.03.001

The effect of long-term treatment with coenzyme Q10 on nucleic acid modifications by oxidation in children with Down syndrome

Emil List Larsen, Lucia Padella, Helle Kirstine Mørup Bergholdt, Trine Henriksen, Lucia Santoro, Orazio Gabrielli, Henrik Enghusen Poulsen, Gian Paolo Littarru, Patrick Orlando, Luca Tiano

Institut for Klinisk Medicin

6 Citationer (Scopus)

Abstract

Elevated levels of oxidative nucleic acid modifications have been proposed to be associated with some of the clinical characteristics of Down syndrome. Oral intake of coenzyme Q10 improves oxidative status and shows a tendency toward protective effect on DNA oxidation in certain age groups of children with Down syndrome. Here, we demonstrate that long-term (i.e., 4 years) treatment with coenzyme Q10 (ubiquinone) at the dosage of 4 mg/kg/d does not affect whole body DNA and RNA oxidation.

Originalsprog	Engelsk
Tidsskrift	Neurobiology of Aging
Vol/bind	67
Sider (fra-til)	159-161
ISSN	0197-4580
DOI	https://doi.org/10.1016/j.neurobiolaging.2018.03.001
Status	Udgivet - jul. 2018

Adgang til dokumentet

10.1016/j.neurobiolaging.2018.03.001

Citationsformater

Larsen, E. L., Padella, L., Bergholdt, H. K. M., Henriksen, T., Santoro, L., Gabrielli, O., Poulsen, H. E., Littarru, G. P., Orlando, P., & Tiano, L. (2018). The effect of long-term treatment with coenzyme Q10 on nucleic acid modifications by oxidation in children with Down syndrome. Neurobiology of Aging, 67, 159-161. https://doi.org/10.1016/j.neurobiolaging.2018.03.001

@article{6a32658c2d2941668695d6b7b39b35a5,

title = "The effect of long-term treatment with coenzyme Q10 on nucleic acid modifications by oxidation in children with Down syndrome",

abstract = "Elevated levels of oxidative nucleic acid modifications have been proposed to be associated with some of the clinical characteristics of Down syndrome. Oral intake of coenzyme Q10 improves oxidative status and shows a tendency toward protective effect on DNA oxidation in certain age groups of children with Down syndrome. Here, we demonstrate that long-term (i.e., 4 years) treatment with coenzyme Q10 (ubiquinone) at the dosage of 4 mg/kg/d does not affect whole body DNA and RNA oxidation.",

keywords = "Administration, Oral, Biomarkers/urine, Child, DNA/metabolism, Deoxyadenosines/urine, Down Syndrome/drug therapy, Guanine/analogs & derivatives, Humans, Oxidation-Reduction/drug effects, Oxidative Stress/drug effects, RNA/metabolism, Time Factors, Ubiquinone/administration & dosage",

author = "Larsen, {Emil List} and Lucia Padella and Bergholdt, {Helle Kirstine M{\o}rup} and Trine Henriksen and Lucia Santoro and Orazio Gabrielli and Poulsen, {Henrik Enghusen} and Littarru, {Gian Paolo} and Patrick Orlando and Luca Tiano",

year = "2018",

month = jul,

doi = "10.1016/j.neurobiolaging.2018.03.001",

language = "English",

volume = "67",

pages = "159--161",

journal = "Neurobiology of Aging",

issn = "0197-4580",

publisher = "Elsevier",

}

TY - JOUR

T1 - The effect of long-term treatment with coenzyme Q10 on nucleic acid modifications by oxidation in children with Down syndrome

AU - Larsen, Emil List

AU - Padella, Lucia

AU - Bergholdt, Helle Kirstine Mørup

AU - Henriksen, Trine

AU - Santoro, Lucia

AU - Gabrielli, Orazio

AU - Poulsen, Henrik Enghusen

AU - Littarru, Gian Paolo

AU - Orlando, Patrick

AU - Tiano, Luca

PY - 2018/7

Y1 - 2018/7

N2 - Elevated levels of oxidative nucleic acid modifications have been proposed to be associated with some of the clinical characteristics of Down syndrome. Oral intake of coenzyme Q10 improves oxidative status and shows a tendency toward protective effect on DNA oxidation in certain age groups of children with Down syndrome. Here, we demonstrate that long-term (i.e., 4 years) treatment with coenzyme Q10 (ubiquinone) at the dosage of 4 mg/kg/d does not affect whole body DNA and RNA oxidation.

AB - Elevated levels of oxidative nucleic acid modifications have been proposed to be associated with some of the clinical characteristics of Down syndrome. Oral intake of coenzyme Q10 improves oxidative status and shows a tendency toward protective effect on DNA oxidation in certain age groups of children with Down syndrome. Here, we demonstrate that long-term (i.e., 4 years) treatment with coenzyme Q10 (ubiquinone) at the dosage of 4 mg/kg/d does not affect whole body DNA and RNA oxidation.

KW - Administration, Oral

KW - Biomarkers/urine

KW - Child

KW - DNA/metabolism

KW - Deoxyadenosines/urine

KW - Down Syndrome/drug therapy

KW - Guanine/analogs & derivatives

KW - Humans

KW - Oxidation-Reduction/drug effects

KW - Oxidative Stress/drug effects

KW - RNA/metabolism

KW - Time Factors

KW - Ubiquinone/administration & dosage

U2 - 10.1016/j.neurobiolaging.2018.03.001

DO - 10.1016/j.neurobiolaging.2018.03.001

M3 - Journal article

C2 - 29665577

SN - 0197-4580

VL - 67

SP - 159

EP - 161

JO - Neurobiology of Aging

JF - Neurobiology of Aging

ER -

The effect of long-term treatment with coenzyme Q10 on nucleic acid modifications by oxidation in children with Down syndrome

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater